BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 20635962)

  • 1. Immunotherapy for Alzheimer's disease.
    Steinitz M
    Immunotherapy; 2009 May; 1(3):461-9. PubMed ID: 20635962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies.
    Geylis V; Steinitz M
    Autoimmun Rev; 2006 Jan; 5(1):33-9. PubMed ID: 16338209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulin and Alzheimer's disease immunotherapy.
    Solomon B
    Curr Opin Mol Ther; 2007 Feb; 9(1):79-85. PubMed ID: 17330405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active vaccination with ankyrin G reduces β-amyloid pathology in APP transgenic mice.
    Santuccione AC; Merlini M; Shetty A; Tackenberg C; Bali J; Ferretti MT; McAfoose J; Kulic L; Bernreuther C; Welt T; Grimm J; Glatzel M; Rajendran L; Hock C; Nitsch RM
    Mol Psychiatry; 2013 Mar; 18(3):358-68. PubMed ID: 22688190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.
    Panza F; Frisardi V; Imbimbo BP; D'Onofrio G; Pietrarossa G; Seripa D; Pilotto A; Solfrizzi V
    Immunotherapy; 2010 Nov; 2(6):767-82. PubMed ID: 21091109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
    Panza F; Logroscino G; Imbimbo BP; Solfrizzi V
    Curr Opin Psychiatry; 2014 Mar; 27(2):128-37. PubMed ID: 24445401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methods to monitor monocytes-mediated amyloid-beta uptake and phagocytosis in the context of adjuvanted immunotherapies.
    Hallé M; Tribout-Jover P; Lanteigne AM; Boulais J; St-Jean JR; Jodoin R; Girouard MP; Constantin F; Migneault A; Renaud F; Didierlaurent AM; Mallett CP; Burkhart D; Pilorget A; Palmantier R; Larocque D
    J Immunol Methods; 2015 Sep; 424():64-79. PubMed ID: 26002154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.
    Rakover I; Arbel M; Solomon B
    Neurodegener Dis; 2007; 4(5):392-402. PubMed ID: 17536186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward.
    Panza F; Solfrizzi V; Imbimbo BP; Tortelli R; Santamato A; Logroscino G
    Expert Rev Clin Immunol; 2014 Mar; 10(3):405-19. PubMed ID: 24490853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripherally administered sera antibodies recognizing amyloid-β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3× Tg-AD mice.
    Wang HC; Yu YZ; Liu S; Zhao M; Xu Q
    Vaccine; 2016 Apr; 34(15):1758-66. PubMed ID: 26945100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracerebroventricular passive immunization in transgenic mouse models of Alzheimer's disease.
    Chauhan NB; Siegel GJ
    Expert Rev Vaccines; 2004 Dec; 3(6):717-25. PubMed ID: 15606357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current trend of immunotherapy for Alzheimer's disease].
    Matsumoto SE; Tabira T
    Nihon Rinsho; 2011 Sep; 69(9):1628-32. PubMed ID: 21922765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Aβ immunotherapy for Alzheimer's disease].
    Sakai K; Yamada M
    Brain Nerve; 2013 Apr; 65(4):461-8. PubMed ID: 23568994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective neutralization of APP-C99 with monoclonal antibodies reduces the production of Alzheimer's Aβ peptides.
    Houacine J; Bolmont T; Aeschbach L; Oulad-Abdelghani M; Fraering PC
    Neurobiol Aging; 2012 Nov; 33(11):2704-14. PubMed ID: 22317957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model.
    Dodart JC; Bales KR; Gannon KS; Greene SJ; DeMattos RB; Mathis C; DeLong CA; Wu S; Wu X; Holtzman DM; Paul SM
    Nat Neurosci; 2002 May; 5(5):452-7. PubMed ID: 11941374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans.
    Lemere CA; Maier M; Jiang L; Peng Y; Seabrook TJ
    Rejuvenation Res; 2006; 9(1):77-84. PubMed ID: 16608400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization in Alzheimer's disease: naïve hope or realistic clinical potential?
    Foster JK; Verdile G; Bates KA; Martins RN
    Mol Psychiatry; 2009 Mar; 14(3):239-51. PubMed ID: 18957942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence supporting a role for anti-Abeta antibodies in the treatment of Alzheimer's disease.
    Morgan D; Gitter BD
    Neurobiol Aging; 2004; 25(5):605-8. PubMed ID: 15172737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.